Lina El Kibbi

ORCID, self-asserted

ORCID 0000-0003-1710-9996

Publications

Citations

144

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

8 works in the graph, newest first.

Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
2024Lara D. VeekenJournalOpen access1 citations10.1093/rheumatology/keae128
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period—a cross-sequential study based on COVAD surveys
2023Lara D. VeekenJournalOpen access35 citations10.1093/rheumatology/kead144
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
2023Lara D. VeekenJournalOpen access18 citations10.1093/rheumatology/kead057
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys
2023Lara D. VeekenJournalOpen access10 citations10.1093/rheumatology/kead180
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
2023Rheumatology InternationalJournalOpen access10 citations10.1007/s00296-023-05345-y
Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
2023Lara D. VeekenJournalOpen access8 citations10.1093/rheumatology/kead149
Flares of autoimmune rheumatic disease following COVID ‐19 infection: Observations from the COVAD study
2023International Journal of Rheumatic DiseasesJournalOpen access7 citations10.1111/1756-185x.14961
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
2023Lara D. VeekenJournalOpen access4 citations10.1093/rheumatology/kead382